The antiarrhythmic drug amiodarone has a long half-life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis.
| INTRODUCTION
Amiodarone is a class III antiarrhythmic drug used for rhythm control in patients with atrial fibrillation. In the Netherlands, it is preserved as a second-line treatment because of its various side effects. 1, 2 Amiodarone is a highly fat-soluble drug and accumulates in the body after long-term use. 3 This results in a long half-life of about 60 days (range 9-107 d), 1, [3] [4] [5] [6] which increases with longer exposure to amiodarone. 7 As a consequence, both the positive and the adverse effects of amiodarone mainly occur after prolonged use, when the drug has accumulated in the body. 8, 9 Adverse reactions may therefore also occur several weeks to months after discontinuation of the intake of amiodarone.
The long half-life of amiodarone may have consequences for observational studies of the effects of the drug. In such studies, information about exposure to amiodarone is mostly based on prescription or dispensing information. Assuming that patients take their pills as prescribed, the resulting exposure classification may inadequately reflect actual exposure status as the patient might be much longer physically exposed because of the long half-life. However, in observational studies of adverse effects of amiodarone, these pharmacokinetic characteristics are not always considered when defining exposure to amiodarone. In fact, exposure to amiodarone has been defined in different ways, eg, ever vs never use 10 ; current/recent/past use vs never use 11 ; recent vs nonrecent use 12 ; cumulative dose 10, 13 ; and duration of use. 14 An exception to this is the study by Taylor et al who accounted for the relatively long half-life of amiodarone by extending the exposure period with 2 months after discontinuation of use. 15 Various exposure definitions were also used in research into the association between amiodarone use and the risk of acute pancreatitis. Whether acute pancreatitis is a direct or cumulative effect is still unclear. Case reports on use of amiodarone and the occurrence of acute pancreatitis suggest either an immediate reaction (3-5 d following initiation) 16, 17 or a cumulative effect (1-36 mo following initiation). 18, 19 The association between amiodarone and acute pancreatitis has been investigated in two case-control studies, both using different definitions for amiodarone exposure.
In the study by Lai et al, a comparison was made between current use (most recent prescription < 3 mo before the event) and never use, which resulted in an odds ratio (OR) of 5.21 (95% confidence interval [CI], 3.22-8.43). 11 Alsonso et al compared ever use of amiodarone before the event date with never use. This resulted in an OR of 1.53 (95% CI, 1.24-1.88). 10 These very different effect estimates are possibly due to the different methods of defining exposure to amiodarone. In addition, both studies did not take into account the pharmacokinetic properties of amiodarone.
The aim of this study is therefore to investigate the impact of different amiodarone exposure definitions on the association between amiodarone and the risk of acute pancreatitis, taking into account the pharmacokinetic properties.
| METHODS

| Data source
Data were obtained from the PHARMO Database Network in the Netherlands, which includes information about more than four million inhabitants of the Netherlands (approximately 25% of the Dutch population) with an average follow-up of 10 years. 20 
| Study population
All subjects in the Out-patient Pharmacy Database with a first dispensing of the class III antiarrhythmic drug amiodarone (ATC code C01BD01) between 1 January 2005 and 31 December 2013 were included in the study. The comparison group consisted of all subjects with a first dispensing of a class I or III antiarrhythmic drug other than amiodarone during the same period (ATC code C01B, excl C01BD01).
The date of the first dispensing was defined as index date for both groups. Inclusion criteria for both groups were an age of ≥18 years at the index date and the presence of at least 6 months of enrolment in the database prior to the index date to ensure the selection of incident users. All subjects with a known history of acute pancreatitis in the 6 months before the index date were excluded.
KEY POINTS
• Amiodarone has a long half-life of 60 days, so both the positive as well as the adverse effects of amiodarone may occur several weeks to months after discontinuation.
• Different exposure definitions that may or may not take into account these pharmacokinetic properties may result in different effect estimates.
• The relation of amiodarone and acute pancreatitis was in this study found to be relatively insensitive against a broad range of different exposure definitions.
Each subject was followed up until acute pancreatitis was diagnosed, death, deregistration from the concerning pharmacy, or the end of the study period, whichever came first. Subjects were allowed to switch from amiodarone to another antiarrhythmic drug, to use both types of drugs at the same time, or to stop using any antiarrhythmic medication. This was taken into account in the analysis (see Section 2.6).
| Outcome definition
Occurrence of acute pancreatitis was defined using the hospitalization data. ICD-9 code 577.0 was used for identification of the outcome. 23 
| Exposure definitions
Days exposed was identified on the basis of the theoretical duration of each individual dispensing. The assessment was based on the dispensing date, quantity dispensed, strength, and written dosage instruction of each dispensing. In case of unknown dosage instructions (<1% of all amiodarone dispensings), the maintenance dose was set at 1 daily defined dose (DDD), 200 mg once daily. 21 Treatment with amiodarone usually starts with a loading scheme. Therefore, a standard loading scheme was applied to all dispensings in which a loading scheme was mentioned, on the basis of the most frequently applied scheme in the study population: 7 days 3 × 200 mg followed by 7 days 2 × 200 mg. Several exposure definitions were applied, which we describe below (see Figure 1 for illustration).
| Dichotomous exposure definitions
Intention to treat
All subjects with an index dispensing of amiodarone were considered as exposed to amiodarone throughout the whole follow-up. All other subjects were defined as nonexposed. This definition can lead to a biased estimate of the relation between actual amiodarone use and risk of pancreatitis because it ignores the duration of amiodarone treatment; a treatment duration of 1 week could, for example, result in an "exposure episode" of 9 years. Nevertheless, it was used in previous research on the adverse events of amiodarone and therefore included in our analysis to allow for comparison.
Current use vs noncurrent use
All constructed episodes of exposure were considered as "current use." In the first definition of "current use," overlapping periods and gaps between two dispensings were ignored. For the second definition, overlapping periods between two dispensings were added to the end of the concerning exposure episode, with a maximum of 90 days. Gaps were still ignored. For the third definition, these "overlapadjusted" episodes of current use were additionally prolonged with different washout periods of 30, 60, and 90 days. When these washout periods had overlap with a subsequent exposure episode, this overlap was not added to the end of the next episode.
| Continuous exposure definitions
Current dose "Current dose" was defined as the dose in DDD during the episodes of "current use" after correction for overlapping periods. Different washout periods were applied (30, 60, and 90 d). During these washout periods, the dose was considered to be equal to the latest dispensed dose. 
Kinetic dose-model
| Categorized exposure definitions
Cumulative exposure
The cumulative exposure was expressed as number of DDDs. The resulting cumulative dose was then divided into three categories-1 to 90 DDD, 91 to 360 DDD, and >360 DDD-to enable a comparison between short-term, medium-term, and long-term users. The cumulative dose was a time-dependent variable. Two different definitions were applied: "overall cumulative exposure" and "cumulative exposure within episode." Overall cumulative exposure was defined as the amount of DDDs dispensed during the whole study period, starting from 0 and accumulating with each day of use. After each exposure episode, the cumulative dose did not change, until a new exposure episode started.
In the second definition, the cumulative dose was calculated for each episode separately, starting each episode from 0 and accumulating with each day of use. When there were gaps between two dispensings, the cumulative dose was set to 0 at the end of a treatment episode and started again from 0 when a new episode started. In addition to this definition, a washout period (30, 60, and 90 d) was added to each exposure period. In this washout period, the cumulative dose was held constant and started from that level when a new dispensing started within the washout period. When no new prescription was dispensed during the washout period, the cumulative dose was set to 0 after the washout period and started again from 0 when a new episode started.
| Potential confounders
Potential confounders that were considered as covariates in the models were age, sex, comorbidities (diabetes mellitus, hypertriglyceridemia, and biliary stones), and (co)medication use (antiarrhythmic drugs, acetaminophen, opiates, simvastatin, atorvastatin, enalapril, estrogens, furosemide, hydrochlorothiazide, doxycycline, and steroids), because these have been reported as possible risk factors for developing acute pancreatitis. 24 ATC and ICD codes for both comedication and comorbidities are included in Table S1.
| Data analysis
The characteristics of subjects included in the study were determined These covariates were selected on their low prevalence and/or the strength of their relationship with the outcome. In addition, two sensitivity analyses were performed. The first sensitivity analysis excluded all subjects exposed for more than 95% of their follow-up time, since in these subjects, the different exposure definitions would not result in very different patterns of exposure. In the second sensitivity analysis, all amiodarone users with baseline use of another antiarrhythmic drug were excluded to minimize the risk of confounding by indication.
The assumption of proportional hazard functions over time was checked graphically with a "log-log" plot. Data analysis was performed using the statistical software package R. 25 
| RESULTS
On the basis of cohort entry medication, the study included 15 378 amiodarone starters and 21 394 starters of other antiarrhythmic drugs. The characteristics of the study populations are presented in Table 1 28.8% of all subjects exposed for more than 95% of their follow-up time. There were 75 pancreatitis events during the study period, 45 among the amiodarone starters and 30 among the starters of other antiarrhythmic drugs. Median time-to-event was 857 days after starting with amiodarone and 686 days after starting with another antiarrhythmic drug.
The effects of amiodarone exposure on the risk of acute pancreatitis are presented in Table 2 and Figure 2 Most of the variation in HR was seen when cumulative exposure was measured in different categories, with subjects switching differently between the categories for each different definition. Depending on the definition used, the adjusted HR varied between 0.52 (95% CI, 0.16-1.72) for the cumulative use of more than 360 DDD and 1.72 (95% CI, 0.78-3.81) for the use of 1 to 90 DDD, both for cumulative dose within an episode and when no washout or gap was allowed.
The results of the two sensitivity analyses in which all amiodarone users exposed for more than 95% of their follow-up time or with a baseline use of another antiarrhythmic drug were excluded did not show any relevant differences in the estimates (Tables S2 and S3 ).
| DISCUSSION
In this study, we found no association between exposure to amiodarone and the risk of acute pancreatitis within a cohort of antiarrhythmic drug users. The different ways of defining exposure to amiodarone did not result in materially different effect estimates. Case reports on use of amiodarone and the occurrence of acute pancreatitis suggest either an idiosyncratic reaction (3-5 d following initiation) 16, 17 or a cumulative effect (1-36 mo following initiation). 18, 19 In our data, we observed a median time to hospitalization for pancreatitis of 857 days since starting amiodarone with an interquartile range of 341 to 1361 days, suggesting that this effect is a cumulative effect, possibly related to the plasma concentrations of amiodarone as reflected by the kinetic dose model.
One potential limitation of our study was the low predictive value of the outcome, since ICD-9 code 577.0 does not differentiate between different causes of acute pancreatitis, such as drug-induced, alcoholic, biliary, and idiosyncratic pancreatitis. The effect estimates found in our study reflect thus the relation between amiodarone and "all-cause pancreatitis." In general, it is not advisable to exclude cases with a "known" cause. 26 The effect of amiodarone use on drug-induced pancreatitis is likely to be diluted if we assume that the amiodarone use is not associated with the other forms of acute pancreatitis.
A second limitation was the small number of events and consequently limited power to show differences between the effect estimates from the different exposure definitions if such differences exist. Furthermore, discontinuation of amiodarone treatment was uncommon in the population. More than a quarter of all subjects were exposed to amiodarone for more than 95% of the duration of the follow-up, leaving no room for lag periods or changes in the kinetic dose. Sensitivity analyses in which subjects exposed for more than 95% of their follow-up time were excluded did however not result in different estimates, yet the power was even lower in these analyses.
Another limitation of our study concerns the kinetic dose definition.
In this study, the half-life was assumed to be the same for all individuals, but this is rather a simplification of reality. The half-life varies between subjects, probably caused by a different distribution of fatty tissue, 4 of which no information is available in the used database.
There was also no information available on the alcohol consumption, which is a known risk factor for acute pancreatitis, thus potentially resulting in unmeasured confounding.
To conclude, in this study, the association between amiodarone and the risk of acute pancreatitis was insensitive for a broad range of different exposure definitions. Accounting for lagged effects had little impact, possibly because treatment switching was uncommon in this population. To further assess the impact of different exposure definitions in research practice, we recommend replication of this study in larger databases, with more variation in amiodarone use.
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FIGURE 2
Hazard ratios (HRs) of exposure to amiodarone compared with exposure to another antiarrhythmic drug and the risk of acute pancreatitis. † HR expressed for being exposed vs nonexposed. ‡ HR expressed per 1 daily defined dose (DDD). § HR expressed for steadystate dose. ¶ HR expressed for this category vs nonuse or past-use (past-use is not applicable when no reset was applied). HRs adjusted for age, sex, diabetes mellitus, hypertriglyceridemia, biliary stones, antiarrhythmic drugs, acetaminophen, opiates, atorvastatin, furosemide, hydrochlorothiazide, doxycycline, and steroids.
